Cargando…

Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment

Hepatocellular carcinoma (HCC) exerts huge effects on the health burden of the world because of its high mortality and poor prognosis. HCC is often clinically detected late in patients. If HCC could be detected and treated earlier, the survival rate of patients will be greatly improved. Therefore, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Mengtao, Wang, Xinzhi, Kiken, Robert A., He, Ling, Zhang, Jian-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201127/
https://www.ncbi.nlm.nih.gov/pubmed/34200243
http://dx.doi.org/10.3390/ijms22116139
_version_ 1783707745100234752
author Xing, Mengtao
Wang, Xinzhi
Kiken, Robert A.
He, Ling
Zhang, Jian-Ying
author_facet Xing, Mengtao
Wang, Xinzhi
Kiken, Robert A.
He, Ling
Zhang, Jian-Ying
author_sort Xing, Mengtao
collection PubMed
description Hepatocellular carcinoma (HCC) exerts huge effects on the health burden of the world because of its high mortality and poor prognosis. HCC is often clinically detected late in patients. If HCC could be detected and treated earlier, the survival rate of patients will be greatly improved. Therefore, identifying specific biomarkers is urgent and important for HCC. The liver is also recognized as an immune organ. The occurrence of HCC is related to exacerbation of immune tolerance and/or immunosurveillance escape. The host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy, as can be seen from the clinical success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Thus, there is a pressing medical need to discover immunodiagnostic biomarkers specific to HCC for understanding the pathological mechanisms of HCC, especially for immunotherapy targets. We have reviewed the existing literature to summarize the immunodiagnostic markers of HCC, including autoantibodies against tumor-associated antigens (TAAs) and exosomes, to provide new insights into HCC and early detection of this deadly cancer.
format Online
Article
Text
id pubmed-8201127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82011272021-06-15 Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment Xing, Mengtao Wang, Xinzhi Kiken, Robert A. He, Ling Zhang, Jian-Ying Int J Mol Sci Review Hepatocellular carcinoma (HCC) exerts huge effects on the health burden of the world because of its high mortality and poor prognosis. HCC is often clinically detected late in patients. If HCC could be detected and treated earlier, the survival rate of patients will be greatly improved. Therefore, identifying specific biomarkers is urgent and important for HCC. The liver is also recognized as an immune organ. The occurrence of HCC is related to exacerbation of immune tolerance and/or immunosurveillance escape. The host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy, as can be seen from the clinical success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Thus, there is a pressing medical need to discover immunodiagnostic biomarkers specific to HCC for understanding the pathological mechanisms of HCC, especially for immunotherapy targets. We have reviewed the existing literature to summarize the immunodiagnostic markers of HCC, including autoantibodies against tumor-associated antigens (TAAs) and exosomes, to provide new insights into HCC and early detection of this deadly cancer. MDPI 2021-06-07 /pmc/articles/PMC8201127/ /pubmed/34200243 http://dx.doi.org/10.3390/ijms22116139 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xing, Mengtao
Wang, Xinzhi
Kiken, Robert A.
He, Ling
Zhang, Jian-Ying
Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title_full Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title_fullStr Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title_full_unstemmed Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title_short Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
title_sort immunodiagnostic biomarkers for hepatocellular carcinoma (hcc): the first step in detection and treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201127/
https://www.ncbi.nlm.nih.gov/pubmed/34200243
http://dx.doi.org/10.3390/ijms22116139
work_keys_str_mv AT xingmengtao immunodiagnosticbiomarkersforhepatocellularcarcinomahccthefirststepindetectionandtreatment
AT wangxinzhi immunodiagnosticbiomarkersforhepatocellularcarcinomahccthefirststepindetectionandtreatment
AT kikenroberta immunodiagnosticbiomarkersforhepatocellularcarcinomahccthefirststepindetectionandtreatment
AT heling immunodiagnosticbiomarkersforhepatocellularcarcinomahccthefirststepindetectionandtreatment
AT zhangjianying immunodiagnosticbiomarkersforhepatocellularcarcinomahccthefirststepindetectionandtreatment